Lisata Therapeutics, Inc. (8NE.F)
Lisata Therapeutics, Inc.
110 Allen Road
2nd Floor
Basking Ridge, NJ 07920
United States
908 842 0100
https://www.lisata.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 25
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. | President, CEO & Director | 1.02M | N/D | 1957 |
| Dr. Kristen K. Buck M.D. | Executive VP of R&D and Chief Medical Officer | 818.3k | N/D | 1974 |
| Mr. James Nisco | Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer | N/D | N/D | 1971 |
| Mr. Tariq Imam | Vice President of Business Development & Operations and Corporate Counsel | N/D | N/D | N/D |
| Mr. Gregory S. Berkin | Chief Information Officer | N/D | N/D | N/D |
| Mr. John D. Menditto | Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Ms. Gail Holler | Vice President of Human Resources | N/D | N/D | 1959 |
| Dr. William K. Sietsema Ph.D. | Vice President of Global Regulatory Affairs | 327.37k | N/D | 1956 |
Descripción
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de Lisata Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
